MSI Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about MSI clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 2

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Gastric CancerMetastatic CancerAdvanced Cancer+1 more
Centre Leon Berard132 enrolled3 locationsNCT06346197
Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

Colo-rectal Cancer (dMMR/MSI-H CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT07352280
Recruiting
Early Phase 1

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Endometrial CancerNon-small Cell Lung CancerTNBC - Triple-Negative Breast Cancer+6 more
Radiopharm Theranostics, Ltd30 enrolled5 locationsNCT06305962
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Colorectal, CancerGastric CancerEndometrial Cancer+4 more
MOMA Therapeutics132 enrolled13 locationsNCT06974110
Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Liver CancerColorectal, CancerEndometrial Cancer+12 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Liver CancerColorectal, CancerEndometrial Cancer+16 more
Elephas416 enrolled12 locationsNCT05520099
Recruiting
Phase 2

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

Colorectal, CancerNeoadjuvant TherapyMismatch Repair-deficient (dMMR)+1 more
Sun Yat-sen University270 enrolled1 locationNCT03926338
Recruiting
Phase 2

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Esophageal CancerCervical CancerHepatocellular Carcinoma+9 more
Diwakar Davar480 enrolled1 locationNCT07223424
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled4 locationsNCT06362369
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Brain Metastases, AdultColorectal Cancer MetastaticRas (Kras or Nras) Gene Mutation+3 more
Blokhin's Russian Cancer Research Center30 enrolled1 locationNCT06449989
Recruiting
Phase 1Phase 2

A Beta-only IL-2 ImmunoTherapY Study

Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 2

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Colo-rectal CancerMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Fudan University40 enrolled1 locationNCT07003022
Recruiting
Phase 1

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592
Recruiting
Phase 2

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

MelanomaHead and Neck NeoplasmsMSI-H Cancer
University Medical Center Groningen97 enrolled1 locationNCT05483400
Recruiting
Phase 1Phase 2

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 1Phase 2

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Triple-Negative Breast CancerMelanomaCancer+6 more
Simcha IL-18, Inc.316 enrolled6 locationsNCT04787042
Recruiting
Phase 2

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Gastric CancerColon CancerMSI-H+1 more
Peking University38 enrolled1 locationNCT06580574